GAITHERSBURG, Md., Nov. 14,
2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a
biotechnology company dedicated to developing and commercializing
next-generation vaccines for serious infectious diseases, today
announced that it will participate in the Jefferies London
Healthcare Conference. Novavax' recombinant nanoparticle
protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a
topic of discussion.
|
Conference
Details:
|
|
Fireside
Chat
|
|
Date:
|
Wednesday, November
16, 2022
|
|
Time:
|
8:35 – 9:05 a.m.
Greenwich Mean Time (GMT)
|
|
Location:
|
London
|
|
Moderator:
|
Roger Song, M.D.,
CFA
|
|
Novavax
participants:
|
Filip Dubovsky, M.D.,
Executive Vice President, Chief Medical Officer
and John J. Trizzino, Executive Vice President, Chief
Commercial
Officer and Chief Business Officer
|
|
|
|
Conference
|
|
|
Event:
|
Investor
Meetings
|
|
Date:
|
Wednesday, November
16, 2022 – Thursday, November 17, 2022
|
Recordings
A replay of the recorded fireside session
will be available through the Events & presentations page of
the Company's website at ir.novavax.com for 90 days from the
date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a
biotechnology company that promotes improved health globally
through the discovery, development, and commercialization of
innovative vaccines to prevent serious infectious diseases. The
company's proprietary recombinant technology platform harnesses the
power and speed of genetic engineering to efficiently produce
highly immunogenic nanoparticles designed to address urgent global
health needs. The Novavax COVID-19 vaccine has received
authorization from multiple regulatory authorities globally,
including the U.S. Food and Drug Administration, the European
Commission, and the World Health Organization. The vaccine is
currently under review by multiple regulatory agencies worldwide,
including for additional populations and indications such as
adolescents and as a booster. In addition to its COVID-19 vaccine,
Novavax is also currently evaluating its COVID-19-Influenza
Combination (CIC) vaccine candidate in a Phase 1/2 clinical trial,
its quadrivalent influenza investigational vaccine candidate, and
an Omicron strain-based vaccine (NVX-CoV2515) as well as a bivalent
format Omicron-based / original strain-based vaccine. These vaccine
candidates incorporate Novavax' proprietary saponin-based Matrix-M
adjuvant to enhance the immune response and stimulate high levels
of neutralizing antibodies.
For more information, visit www.novavax.com and connect
with us on LinkedIn.
Contacts:
Investors
Erika Schultz | 240-268-2022
ir@novavax.com
Media
Ali Chartan or Giovanna Chandler | 240-709-5563
media@novavax.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-jefferies-london-healthcare-conference-301677468.html
SOURCE Novavax, Inc.